<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002671'>Basal cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>) is the most common human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome (<z:e sem="disease" ids="C0004779,C0812437" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">Gorlin syndrome</z:e>) are highly susceptible to developing many <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> as a result of a constitutive inactivating mutation in one allele of PATCHED 1, which encodes a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor that is a major inhibitor of Hedgehog signaling </plain></SENT>
<SENT sid="2" pm="."><plain>Dysregulated Hedgehog signaling is a common feature of both hereditary and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, we showed remarkable anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> chemopreventive efficacy of <z:chebi fb="0" ids="32184">tazarotene</z:chebi>, a <z:chebi fb="0" ids="26537">retinoid</z:chebi> with <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptor (RAR) beta/gamma specificity, in Ptch1+/- mice when treatment was commenced before carcinogenic insults </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we assessed whether the effect of <z:chebi fb="0" ids="32184">tazarotene</z:chebi> against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> is sustained after its withdrawal and whether <z:chebi fb="0" ids="32184">tazarotene</z:chebi> is effective against preexisting microscopic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> lesions </plain></SENT>
<SENT sid="5" pm="."><plain>We found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> did not reappear for at least 5 months after topical drug treatment was stopped and that already developed, microscopic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCCs</z:e> were susceptible to <z:chebi fb="0" ids="32184">tazarotene</z:chebi> inhibition </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro, <z:chebi fb="0" ids="32184">tazarotene</z:chebi> inhibited a murine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> keratinocyte cell line, ASZ001, suggesting that its effect in vivo is by direct action on the actual <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Down-regulation of Gli1, a target gene of Hedgehog signaling and up-regulation of CRABPII, a target gene of <z:chebi fb="0" ids="26537">retinoid</z:chebi> signaling, were observed with <z:chebi fb="0" ids="32184">tazarotene</z:chebi> treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, we investigated the effects of topical applications of other <z:chebi fb="0" ids="26537">retinoid</z:chebi>-related compounds on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in vivo </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="32184">Tazarotene</z:chebi> was the most effective of the preparations studied, and its effect most likely was mediated by RARgamma activation </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, inhibition of basal RAR signaling in the skin promoted <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, suggesting that endogenous RAR signaling restrains <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> growth </plain></SENT>
</text></document>